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Abstract
Host colonization by lymphotropic c-herpesviruses depends critically on expansion of viral genomes in germinal center (GC)
B-cells. Myc is essential for the formation and maintenance of GCs. Yet, the role of Myc in the pathogenesis of c-
herpesviruses is still largely unknown. In this study, Myc was shown to be essential for the lymphotropic c-herpesvirus
MuHV-4 biology as infected cells exhibited increased expression of Myc signature genes and the virus was unable to expand
in Myc defficient GC B-cells. We describe a novel strategy of a viral protein activating Myc through increased protein stability
resulting in increased progression through the cell cycle. This is acomplished by modulating a physiological post-
translational regulatory pathway of Myc. The molecular mechanism involves Myc heterotypic poly-ubiquitination mediated
via the viral E3 ubiquitin-ligase mLANA protein. EC5S
mLANA modulates cellular control of Myc turnover by antagonizing
SCFFbw7 mediated proteasomal degradation of Myc, mimicking SCFb-TrCP. The findings here reported reveal that modulation
of Myc is essential for c-herpesvirus persistent infection, establishing a link between virus induced lymphoproliferation and
disease.
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Introduction
Myc is a transcription factor that enhances the expression of
genes involved in cellular growth and proliferation. Hence, it is not
surprising that viruses have evolved mechanisms to modulate Myc
to promote their own life cycle. Myc heterodimerizes with Max,
through a basic region/helix-loop-helix/leucine-zipper domain, to
regulate the transcription of specific E-box-containing genes in
response to mitogenic stimuli. Myc functions as a universal
amplifier of gene expression by promoting the transcriptional
elongation of RNA polymerase II driving biomass accumulation
and enhanced cellular bioenergetic pathways [1,2,3]. The
expression of c-myc is tightly regulated with extremely short half-
lives for mRNA and protein. In non-transformed cells, Myc is
continuously subjected to ubiquitination and proteasomal-degra-
dation, resulting in a highly unstable protein with a half-life of
about 15–20 minutes [4]. Several mechanisms of Myc regulation
have been identified that operate at the level of protein stability.
The best characterized mechanism involves the interplay between
phosphorylation at two specific residues and ubiquitination.
Phosphorylation at serine (S) 62 by extracellular signal-regulated
kinase (ERK) stabilizes Myc resulting in enhancement of its
transcription activity. In contrast, phosphorylation of Myc at
threonine (T) 58 by glycogen synthase kinase 3 (Gsk-3), which is
dependent on previous phosphorylation of Myc at S62, leads to
proteasomal degradation of Myc [5]. The mechanism involves the
assembly of homotypic poly-ubiquitin chains on Myc specifically
dependent on lysine (K) 48 linkage by SCF (Skp1/Cul/Fbox)Fbw7
[6,7]. Myc turnover by SCFFbw7 is antagonized by polymerization
of mixed heterotypic poly-ubiquitination chains via SCFb-TrCP on
the N-terminus of Myc [8]. Thus, SCFFbw7 and SCFb-TrCP
assemble different K-linkage poly-ubiquitin chains with function-
ally distinct outcomes on Myc stability, i.e., degradation versus
stability. The physiological relevance of regulating Myc activity
through protein stability is underscored by observations that point
mutations at or near T58, which render Myc resistant to
proteasomal degradation, occur with high frequency in B-cell
lymphomas [9].
Examples of viruses that modulate Myc activity include
Kaposi’s sarcoma associated herpesvirus (KSHV) and Epstein-
Barr virus (EBV). Infection by these c-herpesviruses is character-
ized by the establishment of latent infection in memory B-cells.
Access to this cell type is gained by virus-driven proliferation of
germinal centre (GC) B-cells [10], where virus genomes replicate
and segregate in step with normal cell division. This process is
mediated by episomal maintenance proteins, which include EBV
nuclear antigen-1 (EBNA-1) [11] and latency associated nuclear
antigen (LANA) encoded by ORF73 of c-2-herpesviruses [12].
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Given the essential role of Myc for the initiation and maintenance
of GCs [13,14], it is not surprising that c-herpesviruses have
evolved mechanisms to modulate Myc activity. In the case of
KSHV-associated primary effusion lymphoma, Myc was shown to
be abnormally stabilized [15,16]. The mechanism involves the
direct interaction of the viral protein LANA with Gsk-3 resulting
on reduced levels of Myc T58 phosphorylation [17]. Another
strategy appears to be employed by EBV encoded EBNA-3C
protein. This viral protein was shown to increase the transcrip-
tional activity of Myc through an interaction with both Myc and
SCFSkp2. Surprisingly the mechanism proposed does not involve
poly-ubiquitination but rather the action of SCFSkp2 functioning as
a transcription co-factor for Myc [18].
Here, we utilized murid herpesvirus-4 (HuHV-4) infection of
mice as a model system to address the role of Myc in the
pathogenesis of c-herpesviruses. We show that Myc expression is
required for the expansion of MuHV-4 infection in GC B-cells.
The mechanism involves heterotypic poly-ubiquitination of Myc
mediated through the ElonginC/Cullin5/SOCS (supressors of
cytokine signaling) (EC5S) E3 ubiquitin-ligase activity of mLANA
encoded by ORF73 of MuHV-4. EC5S
mLANA mimics SCFb-TrCP
by antagonizing SCFFbw7-mediated proteasomal turnover of Myc
but unlike the cellular E3 ubiquitin-ligases its activity is not
dependent on the phosphorylation status of Myc. Our results
underscore the importance of modulating Myc activity during c-
herpesvirus driven lymphoproliferation providing a link between
persistent infection and lymphoproliferative disease.
Results
Myc transcriptional activity is up-regulated during MuHV-
4 infection of GC B-cells
Experiments were designed to investigate the role of Myc
expression on gammaherpesvirus pathogenesis. We utilized
MuHV-4 infection of laboratory mice as the model, which is
characterized by the expansion of latently infected B-cells in GCs
and virus persistence in memory B-cells [19]. We analysed the
transcription of several Myc target genes in infected versus non-
infected GC B-cells, purified from the same pool of splenocytes. We
utilized a recombinant MuHV-4 expressing a yellow fluorescent
protein (YFP) [20] to segregate infected (CD19+CD95hiGL7hiYFP+)
from non-infected (CD19+CD95hiGL7hiYFP2) GC B-cells derived
from C57BL/6 mice, at day 13 post-infection. We analysed the
transcription of Myc signature genes involved in cell cycle entry
(encoding for cyclins B1, D1, D2 and E, and cyclin-dependent
kinase 4) andGC B-cell activation (encoding for IL-10, B-ATF,MIF
and CD70). Cyclin D3 was included as a gene non-regulated by
Myc. The transcription of Myc target genes was significantly
increased in infected GC B-cells when compared with their non-
infected counterparts (Figure 1A). These data show that during the
expansion of latent infection in GC B-cells, MuHV-4 induces a
transcription profile compatible with increased Myc transcriptional
activity.
Myc is essential for GC responses
To define the impact of Myc expression on gamma-herpesvirus
pathogenesis, we generated mice with conditional deletion of c-myc
in B-cells undergoing GC reaction. This was achieved by breeding
homozygous c-mycfl/fl mice, where second and third exons of the c-
myc locus are flanked by two loxP sites [21] to heterozygous Cc1-cre
mice, in which expression of Cre recombinase is induced by
transcription of the Ig-c1 constant region gene segment early in
GC development during immunoglobulin class-switch recombi-
nation [22]. Resulting progeny Cc1-creKI/WT;c-mycfl/fl, hereafter
designated GC Myc KO, is expected to have specific deletion of c-
myc in class-switched GC B-cells, after immunization with T-
dependent antigens. Thus, we next investigated GC responses in
the absence of Myc expression. GC Myc KO mice were
immunized with the Th-2 cell-dependent antigen 4-hydroxy-3-
nitrophenylacetyl (NP)–chicken c-globulin (CGG) adsorbed to
alum. Frequencies of GC B-cells (CD19+CD95hiGL7hi) were
analysed at day 10 post-immunization. Compared to control litter
mates Cc1-creWT/WT;c-mycfl/fl, hereafter designated control mice,
GC Myc KO mice showed a marked impairment in GC
development (Figure 1B), accompanied by a strong reduction in
IgG1+ B-cell numbers (CD19+IgD2IgM2IgG1+) (Figure 1C).
Immunization with ovalbumin (OVA) emulsified in complete
Freund’s adjuvant (CFA) further confirmed that GC Myc KO
mice were defective to mount a normal GC response, though less
deficient than upon immunization with NP-CGG, and presented
reduced levels of IgG1 expressing B-cells (Figure 1D and 1E,
respectively). However frequencies of IgG2a/2b+ B-cells
(CD19+IgD2IgM2IgG2a/2b+), whose class-switching is not strict-
ly dependent on Ig-c1 promoter, revealed that GC Myc KO mice
are competent in developing IgG2 class-switched B-cells
(Figure 1F). These data demonstrate a clear requirement for
Myc expression in order to generate GC reactions to T cell
dependent antigens. Our results are in direct agreement with those
recently published that demonstrate the lack of GCs in mice in
which c-myc is ablated early during GC induction [13]. Since we
obtained the two transgenic mice lines carrying the alleles c-mycfl/fl
and Cc1-cre from these authors, and independently generated GC
Myc KO mice, our data are directly comparable.
Myc is critical for the establishment of persistent
infection
The requirement of Myc for gammaherpesvirus pathogenesis
was next investigated by infecting GC Myc KO mice with MuHV-
4. Analysis of the percentages of GC B-cells revealed no significant
differences between control and GC Myc KO mice (Figure 2A),
Author Summary
Being obligatory intracellular parasites, it is not surprising
that viruses have evolved mechanisms to induce cellular
proliferation to promote their own life cycle. This is
notorious in the case of c-herpesviruses, such as Epstein-
Barr virus (EBV) and Kaposi’s sarcoma virus (KSHV), which
are human pathogens associated with lymphoproliferative
disease and several tumors. Host colonization by c-
herpesviruses is critically dependent on the ability to
expand latent infection in proliferating B-cells. Virus-
induced cellular proliferation is a process mediated by
the expression of specific viral proteins. One of such
proteins is the latency-associated protein (LANA) of KSHV.
In this study, we use murid herpesvirus-4 (MuHV-4) as a
mouse model of c-herpesvirus pathogenesis. We show
that the MuHV-4 LANA (mLANA) stabilizes the cellular onco-
gene Myc, increasing its half-life, thus promoting its activity
as a potent inducer of cellular proliferation. The molecular
mechanism involves heterotypic poly-ubiquitination of Myc
mediated via mLANA. The findings here reported demon-
strate that modulation of Myc is essential for c-herpesvirus
persistent infection, establishing a link between virus
induced lymphoproliferation and disease. The implication
is that revealing a critical function of a viral protein possibly
allows the development of small molecule probes to disrupt
mLANA-Myc interaction, therefore inhibit virus induced
lyhophoproliferative disease.
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with the majority of infected GC B-cells falling into dark zone
(Figure 2B) as previously described for infection of wild type mice
[23]. To determine if MuHV-4 infected GC B-cells had been or
not exposed to Cre-mediated c-myc deletion, we FACS purified
infected cells from GC Myc KO mice, at day 14 post-infection. A
PCR assay was employed to detect floxed and deleted c-myc alleles
in DNA from infected GC B-cells, compared to DNA from
uninfected total B-cells (CD19+YFP2), purified from the same pool
Figure 1. Myc transcriptional activity is upregulated during MuHV-4 latency in GC cells. (A) MuHV-4 infected cells exhibit augmented
expression of Myc-dependent genes. FACS purified infected (CD19+CD95hiGL7hiYFP+) or control uninfected (CD19+CD95hiGL7hiYFP2) GC B-cells from
C57BL/6 mice infected with MuHV-4-YFP were analysed at 13 days pi for transcription of genes encoding for cyclins (Cyc) B1, D1, D2, D3, E1, cyclin-
dependent kinase (Cdk) 4, IL10, B-ATF, MIF and CD70 by qPCR. Transcription of each gene, normalized to GAPDH, is represented as fold induction relative
to control uninfected cells purified form the same pool of 5 spleens. Error bars represent SEM from three independent experiments. (B and C) Cc1-creKI/WT;
c-mycfl/fl (GC Myc KO) mice are unable to mount a GC reaction. GC Myc KO and control mice immunized with NP-CGG were analysed at day 10 post-
immunization for frequencies of GC (CD19+CD95hiGL7hi) and IgG1 (CD19+IgD2IgM2IgG1+) B-cells, by flow cytometry. (D, E and F) GCMyc KOmice exhibit
normal numbers of IgG2a/2b B-cells. GC Myc KO and control mice immunized with CFA-OVA were analysed 14 days later for frequencies of GC, IgG1 and
IgG2a/2b (CD19+IgD2IgM2IgG2a/2b+) B-cells by flow cytometry. Each point represents an individual mouse; four mice (n=4) were analyzed for each
experimental condition; grey bars indicate the mean. Representative FACS plots from individual animals are shown (top panels).
doi:10.1371/journal.ppat.1003554.g001
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of splenocytes. Infected cells were found to have undeleted (floxed)
c-myc allele and no c-myc rearrangement could be detected
(Figure 2C). This contrasted with total non-infected B-cell
population where c-myc deletion could be readily detected
(Figure 2C). To further confirm the integrity of the c-myc locus
in infected GC B-cells in GC Myc KO mice, we quantified Myc
mRNA levels. Comparison of GC B-cells from GC Myc KO with
wild type infected mice revealed no significant differences in Myc
transcription (Figure 2D). These data imply that MuHV-4 is
expanding exclusively in GC B-cells where the c-myc locus did not
undergo Cre-mediated deletion. Accordingly, GC Myc KO mice
infected with MuHV-4 were unable to class-switch to IgG1, which
Figure 2. Myc is essential for the amplification of MuHV-4 infection in GC B-cells. (A and B) MuHV-4 infection of GC Myc KO mice leads to
the development of normal GC reactions. (A) GC B-cell percentages were determined by flow cytometry as described in Figures 1B and 1D at day 14
pi. (B) Dark zone (CD19+CD95hiGL7hiCXCR4hiCD86lo) and light zone (CD19+CD95hiGL7hiCXCR4loCD86hi) percentage of infected cells at day 14 pi. Each
point represents an individual mouse; five mice (n = 5) were analyzed for each experimental condition. (C and D) MuHV-4 infected cells from GC Myc
KO mice are genotypically and phenotypically wild type for Myc. (C) Total DNA from FACS purified MuHV-4 infected GC B-cells, from GC Myc KO mice,
was subjected to PCR analysis with primers specific for deleted (D) or floxed (fl) c-myc, as depicted. DNA from total B-cells, in the same pool of
splenocytes, was analysed in parallel as a positive control for D c-myc. (D) Transcription of Myc, normalized to GAPDH, in purified GC B-cells from GC
Myc KO mice is represented as fold induction relative to MuHV-4 infected GC B-cells purified from wild type mice. Error bars represent SEM from three
independent experiments. (E and F) MuHV-4 infection induces a strong IgG2a/2b response. GC Myc KO and control mice were analysed at day 21 pi
for frequencies of IgG1 and IgG2a/2b B-cells by flow cytometry. Each point represents an individual mouse; four mice (n = 4) were analyzed for each
experimental condition; grey bars indicate the mean. Representative FACS plots from individual animals are shown (top panels). (G) MuHV-4 infection
of GC Myc KO mice reveals a deficit in the establishment of latency. GC Myc KO and control mice were analysed at days 14 and 21 pi for frequencies
of viral infection in GC B-cells. Data were obtained from pools of 5 spleens. Error-bars represent the frequency of viral DNA-positive cells with 95%
confidence intervals.
doi:10.1371/journal.ppat.1003554.g002
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is consistent with Myc deficiency in these cells (Figure 2E).
However, these infected mice showed high numbers of IgG2a/2b
positive B-cells, equivalent to infected control mice counterparts
(Figure 2F). Quantification of the frequency of viral DNA positive
cells in GCs, assessed by limiting dilution combined with real time
PCR, showed an approximately 10-fold deficit of latent infection
at 14 days post-infection in GC Myc KO mice (Figure 2G). This
deficit was likely a reflection of infection of B-cells that did not
result in the expansion in GC reactions due to Ig-c1 Cre mediated
c-myc deletion. However, at day 21 post-infection latent viral loads
in control and conditional KO mice were equivalent (Figure 2G),
indicating a recovery from the early deficit in expansion.
Collectively data obtained with GC Myc KO mice demonstrated
that infection with MuHV-4 does not compensate for Myc loss in
GC B-cells and virus is found to amplify exclusively in c-myc intact
cells. Therefore, Myc is essential for the expansion of latently
infected GC B-cells, thus critical for the establishment of persistent
infection.
mLANA promotes Myc transcriptional activity and cell
cycle progression as an EC5S ubiquitin-ligase
We have shown before that the ORF73 protein encoded by
MuHV-4, designated mLANA by homology with the latency
associated nuclear antigen encoded by KSHV, is selectively
transcribed in GC B-cells [24]. Thus mLANA was a strong
candidate to be responsible for the observed increased transcrip-
tion of Myc target genes in MuHV-4 infected GC B-cells. To
address this hypothesis, we analysed the transcription of Myc
target genes in mLANA expressing cells. When compared to
control transfected cells, mLANA expression induced the tran-
scription of all Myc target genes analysed (Figure 3A). Expression
of mLANA had no effect on c-myc mRNA levels indicating that its
putative modulatory effect on Myc was post-transcriptional
(Figure 3B). We have also shown before that mLANA acts as
the substrate recognition factor of an ElonginC-Cullin5-SOCS
(suppressor of cytokine signalling) (EC5S) E3 ubiquitin-ligase
towards the p65/RelA cellular transcription factor NF-kB [25].
The mechanism involves the assembly of an EC5S -like complex,
mediated by a viral unconventional SOCS-box motif present in
mLANA. Hence, we analysed if mLANA-mediated modulation of
transcription of Myc target genes could be attributed to its
function as an E3 ubiquitin-ligase. To this end, we utilized a
previously characterized mLANA mutant, designated mLANA-
SOCS where residues V199, L202, P203 and P206 were
substituted by alanines abrogating E3 ubiquitin-ligase function
[25]. This mutant was no longer able to modulate the expression
of Myc target genes when compared with intact mLANA
(Figure 3A). To define if the observed mLANA modulatory effect
on cellular transcription was Myc specific, we carried out gene
reporter assays using a synthetic Myc reporter plasmid containing
three copies of E-box sequences driving the expression of
luciferase. As expected, overexpression of Myc was translated into
a significant increase on luciferase activity (Figure 3C). Cells
expressing mLANA exhibited comparable levels of luciferase
activity, which increased further when Myc was concomitantly
expressed. In contrast, mLANA-SOCS expression showed no
effect on luciferase levels. We next proceeded to analyse the
modulatory effect of mLANA on Myc in B-cells, which are
physiological more relevant given the tropism of MuHV-4. When
compared to control and mLANA-SOCS transfected cells,
mLANA expression induced the transcription of all Myc target
genes analysed (Figure 3D). As before, expression of mLANA in
A20 B-cells had no effect on c-myc mRNA levels confirming that its
modulatory effect on Myc was post-transcriptional (Figure 3E).
Myc transcriptional activation of genes encoding proteins involved
in cell cycle entry results in transition from G0-G1 to S phase.
Thus, we analysed cell cycle profiles in B-cells expressing mLANA
in comparison to control or mLANA-SOCS. These experiments
showed a clear decrease in the number of mLANA expressing cells
in G1 phase, with a concomitant increase in the number of cells in
S and G2-M phases (Figure 3F). Combined these data indicate
that mLANA is modulating Myc-dependent transcription and
progression through cell cycle in B-cells through its activity as an
EC5S E3 ubiquitin-ligase. Co-immunoprecipitation experiments
also showed that mLANA and Myc exist in the same hetero-
molecular complex in a context of virus infection. This was
Figure 3. mLANA promotes Myc transcriptional activity and cell cycle progression through E3 ubiquitin-ligase activity. (A) mLANA
expressing cells show increased expression of Cyclin (Cyc) and Cyclin-dependent kinase 4 (Cdk4) genes. HEK 293T cells were transfected as indicated
and transcription of Myc target genes was analysed as described in Figure 1A. Error bars represent SEM from four independent transfection
experiments. (B) mLANA expression does not affect Myc mRNA levels. Relative levels of Myc mRNA in mLANA-transfected are shown in comparison to
control cells. Error bars represent SEM from four independent transfection experiments. (C) mLANA activates Myc transcriptional activity dependent
on its SOCS-box motif. HEK 293T cells were transfected with a Myc (E-box) luciferase reporter vector and with the indicated expression plasmids. Error
bars represent SEM from triplicates from three independent transfection experiments. (D) Expression of Myc signature genes involved in cell cycle
entry and B-cell activation is increased under mLANA expression. A20 cells were transiently transfected with GFP-mLANA, GFP-mLANA-SOCS or
control transfected. Transfected cells were FACS-purified based on GFP expression and proceeded to RNA extraction. Transcription of Myc target
genes was analysed as described in Figure 1A. (E) mLANA expression in A20 cells does not affect Myc mRNA levels. Relative levels of Myc mRNA in
mLANA expressing cells are shown in comparison to control cells. (F) Expression of mLANA promotes cell cycle progression through S and G2-M
phases. Cell cycle profiles of A20 cells transfected with GFP, GFP-mLANA or GFP-mLANA-SOCS expressing plasmids were obtained by staining with
Vybrant DyeCycle followed by FACS analysis. Shaded histograms show the cell cycle profile of GFP2 populations, whereas the blue lines represent
GFP+ cells, for each transfection condition. The percentage of cells in each phase of cell cycle was determined using FlowJo software modelled by the
Dean-Jett-Fox method. Three independent experiments were performed for each experimental condition, a representative of which is shown (top).
Error bars represent SEM. (G and H) mLANA and Myc co-immunoprecipitate in the same heteromolecular complex. (G) Lysates from S11 cells
persistently infected with MuHV-4 were immunoprecipitated with an anti-Myc and an irrelevant antibody (anti-Syk) as negative control and analyzed
by immunoblotting as indicated. Representative aliquots of TCL were used to demonstrate expression of Myc and mLANA in this cell line. (H) HEK
293T cells transiently expressing the indicated combinations of proteins (top) were subjected to immunoprecipitation with anti-mLANA antibodies.
The presence of co-immunoprecipitated Myc was assayed by immunoblotting with anti-Myc. (I) mLANA expressing cells present increased levels of
Myc ubiquitination. HEK 293T cells were transiently transfected with the indicated plasmids (top). After culture, total cellular lysates were obtained
and ubiquitinated proteins were pulled down using Ni-NTA beads. The levels of ubiquitinated Myc in each condition were assayed using an anti-Myc.
(J) mLANA mediates ubiquitination of endogenous Myc. HEK 293T cells transiently expressing mLANA, mLANA-SOCS, or control cells were subjected
to immunoprecipitation with an anti-Myc and analysed by immunoblotting with anti-ubiquitin (Ub). (K) mLANA is able to mediate the assembly of
poly-ubiquitin chains on a lysine-free version of Myc (K2Myc). HeLa cells were transiently transfected to express the indicated combinations of
plasmids (top). Ubiquitinated proteins were pulled-down using Ni-NTA beads and resolved by SDS-PAGE. Levels of ubiquitinated WT or K2 Myc were
analysed by immunoblotting. 2, without; +, with; a-, anti; IP, immunoprecipitation; PD, pull down; TCL, total cellular lysates.
doi:10.1371/journal.ppat.1003554.g003
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Figure 4. mLANA modulates Myc activity through the assembly of heterotypic poly-ubiqutin chains. (A) mLANA-mediated poly-
ubiquitination of Myc is dependent on ubiquitin lysine residues (K) 33, 48 and 63. HeLa cells were transfected to express Myc, mLANA and wild type
(WT) or mutant versions of ubiquitin, in which the indicated lysines had been replaced by arginines (R). TCL were subjected to denaturing
immunoprecipitation using anti-Myc and analysed by immunoblotting with anti-ubiquitin. (B) mLANA stimulation of Myc transcriptional activity
requires K33, K48, and K63 of ubiquitin. HeLa cells were transfected with a Myc (E-box) luciferase reporter vector, the indicated ubiquitin mutants,
combined with (open bars) or without (filled bars) mLANA. Myc transcriptional activity was assayed as described in Figure 3C. Error bars represent
SEM from triplicates from three independent transfection experiments. (C) mLANA-expressing cells exhibit increased Myc levels when K33, K48 and
K63 residues of ubiquitin are preserved. HeLa cells were transfected to express the indicated combination of proteins (top) and Myc protein levels
were analysed by immunoblotting. Right panel shows the densitometry analysis of Myc levels in mLANA transfected cells, expressed as fold induction
relative to control transfected cells, normalised to Actin. (D) mLANA requires ubiquitin residues K33, K48 and K63 to mediate the poly-ubiquitination
of the N-terminus of Myc. HeLa cells were transfected to express K2Myc, mLANA and the indicated ubiquitin mutants. Ubiquitination of K2Myc was
assessed as described in A. (E) mLANA modulation of K2Myc transcriptional activity involves ubiquitin residues K33, K48 and K63. HeLa cells were
mLANA-Mediated Enhanced Myc Stability
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demonstrated using a murine B-cell lymphoma-derived cell line
latently infected with MuHV-4, designated S11 cells (Figure 3G).
We also showed that this interaction was reduced for mLANA-
SOCS (Figure 3H, compare lanes 3 and 5). This reduction could
be due to lower levels of Myc in mLANA-SOCS expressing cells,
when compared to mLANA, indicating that the interaction is
independent of the SOCS-box motif. Alternatively it is plausible
that the SOCS-box is participating in mLANA-Myc interaction.
mLANA mediates Myc poly-ubiquitination
We next set out experiments to investigate if EC5S
mLANA was
able to mediate poly-ubiquitination of Myc. We started by
performing a nickel-nitrilotriacetic acid (Ni-NTA) pull-down in
the presence of histidine-tagged ubiquitin. Upon culture and cell
lysis, ubiquitinated proteins were extracted from total cellular
lysates with Ni-NTA beads and resolved by SDS-PAGE. The
levels of ubiquitinated Myc present in each condition were
analysed by immunoblotting. We observed that when mLANA
was expressed, the levels of ubiquitinated Myc were significantly
enhanced (Figure 3I, compare lanes 3 and 4). To confirm this
activity in a more relevant biological context, we evaluated the
ability of mLANA to promote the ubiquitination of endogenously
expressed Myc. In comparison with control transfected and
mLANA-SOCS transfected cells, higher levels of ubiquitinated
Myc were detected in the presence of intact mLANA (Figure 3J,
compare lane 2 with 1 and 3). We have previously demonstrated
that mLANA E3 ubiquitin-ligase activity towards p65/RelA
required the E2 ubiquitin-conjugating enzyme UbcH5 [25]. Here
we showed that EC5S
mLANA requires UbcH5 as its E2 conjugating
partner to mediate poly-ubiquitination of Myc (Figure S1). Myc
protein has 25 lysine residues that can be potentially ubiquitinated.
To define if the ubiquitination ladder observed was due to the
ability of mLANA to mediate poly-ubiquitination or multiple
mono-ubiquitination of Myc in different lysine residues, we made
use of a previously described lysine-free (K2) version of Myc,
which can only be ubiquitinated on its N-terminal residue [8]. By
performing an in vivo ubiquitination assay with K2Myc, we
observed the following. First, mLANA was able to mediate poly-
ubiquitination of the N-terminal residue of Myc (Figure 3K,
compare lanes 3 and 4). Secondly, K2Myc in the presence of
mLANA exhibited a ladder of ubiquitination indicating the
assembly of poly-ubiquitin chains (Figure 3K, compare lanes 3
and 4). Finally, the ubiquitination pattern of wild type Myc and
K2Myc are distinctive, implicating that other lysine residue(s) are
targets for mLANA-mediated poly-ubiquitination of Myc.
EC5S
mLANA assembles heterotypic poly-ubiquitin chains
on Myc
The addition of ubiquitin chains to a target protein can occur
with different moieties that are emerging as determinants of
biological outcome. These include, mono-ubiquitination and poly-
ubiquitination. Ubiquin chains can be assembled using seven
internal lysine residues (K) and thus define homotypic poly-
ubiquitination (same K-linkage) or heterotypic poly-ubiquitination
(mixed K-linkages) [26]. To investigate the type of lysine (K)-
linkage involved in mLANA-mediated poly-ubiquitination of Myc
we utilized of a series of ubiquitin mutants with every single lysine
residue, of the possible seven, substituted by an arginine. By
performing in vivo ubiquitination assays in mLANA expressing
cells we observed that in the absence of K33, K48 or K63 residues
the ability of mLANA to promote Myc poly-ubiquitination was
suppressed (Figure 4A). Next, Myc transcription reporter assays
were carried out in cells expressing the same ubiquitin mutants.
Consistent with the poly-ubiquitination pattern, replacement of
K33, K48 and K63 in ubiquitin rendered mLANA unable to
positively modulate Myc transcriptional activity (Figure 4B).
Measurement of Myc cellular levels in extracts from mock
transfected control or mLANA-transfected cells co-expressing
each ubiquitin mutant, revealed that in the presence of wild type
ubiquitin, mLANA-expressing cells exhibit augmented Myc levels
(Figure 4C, upper panel, compare lanes 1 and 2). The same result
is observed when residues K6, K11, K27 and K29 of ubiquitin
were substituted by arginines (Figure 4C, upper and lower panels).
However, in good agreement with the previous data, substitution
of K33, K48 and K63, diminished or abolished the ability of
mLANA to promote the increase in Myc cellular levels (Figure 4C).
Our observations demonstrate the involvement of different lysine-
linkages in EC5S
mLANA Myc poly-ubiquitination. However, these
data do not distinguish between homotypic poly-ubiquitination at
different K residues in Myc from mixed K-linkage poly-
ubiquitination. Hence, we next utilized K2Myc where ubiquitina-
tion is only possible at the first metionine. In vivo ubiquitination
assays and transcription reporter assays with K2Myc, in combi-
nation with each of the K ubiquitin mutants, essentially
recapitulated the above observed results with wild type Myc
(Figure 4D and E). Hence, heterotypic poly-ubiquitination of the
N-terminus of Myc is sufficient for mLANA modulatory activity.
Collectively, these data show that EC5S
mLANA requires different
K-linkages to ubiquitinate Myc. Moreover, they demonstrate a
direct correlation between the ability of mLANA to mediate Myc
poly-ubiquitination, to increase Myc cellular levels, and to
promote its transcriptional activity, supporting that all three
activities are directly linked.
mLANA poly-ubiquitination on Myc is non-degradative
Although classically associated with protein degradation,
ubiquitination is now emerging as regulator of a wide variety of
non proteolytic cellular signalling functions [26]. Therefore, and in
agreement with a positive effect on Myc activity, we further
confirmed that mLANA-mediated poly-ubiquitination of Myc was
non-degradative. To that end, we performed an in vivo
ubiquitination assay in the presence of the proteasome inhibitor
MG132. In control-transfected cells, the presence of MG132
favoured the accumulation of Myc ubiquitinated species
(Figure 5A, top panel, compare lanes 1 and 2), as well as the
cellular levels of Myc protein (Figure 5A, bottom panel, compare
lanes 1 and 2). In contrast, in cells expressing mLANA, inhibition
of proteasomal degradation had a negligible influence on both
Myc poly-ubiquitination and Myc protein levels (Figure 5A,
compare lanes 3 and 4). The importance of these results is
threefold. Firstly, they confirm that under physiological conditions
Myc turnover is highly regulated by the proteasome. Secondly,
they show that treatment with the proteasome inhibitor MG132
has no effect on mLANA-mediated poly-ubiquitination of Myc,
thus mLANA in not directing Myc for proteasomal degradation.
Thirdly, the increase in Myc levels in response to mLANA
expression was not altered under conditions of proteasomal
inhibition, suggesting that expression of mLANA is preventing
transfected to express K2Myc, the indicated ubiquitin mutants, mLANA (open bars) or control transfected (grey bars). Myc transcriptional activity was
assayed as described in Figure 3C. Error bars represent SEM from triplicates from three independent transfection experiments. 2, without; +, with; a-,
anti; IP, immunoprecipitation; TCL, total cellular lysates.
doi:10.1371/journal.ppat.1003554.g004
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the proteasomal degradation of Myc. To assess this hypothesis, we
next compared the half-life of Myc in control and mLANA
expressing cells. Cells were treated with the protein synthesis
inhibitor cycloheximide (CHX), and Myc protein levels were
analyzed by immunoblotting at different time-points post-treat-
ment. Under these experimental conditions, expression of
mLANA led to a pronounced raise in Myc stability with an
increase of half-life from <20 minutes to over 4 hours (Figure 5B).
Figure 5. EC5S
mLANA mimics SCFb-TrCP by antagonizing SCFFbw7-mediated proteasomal turnover of Myc. (A) mLANA-mediated poly-
ubiquitination of Myc is non-degradative. Cells transfected with the indicated plasmids were treated with MG132 (10 mM) for 8 h, or left untreated as
depicted. Myc poly-ubiquitination was assayed as described in Figure 3F. (B) Myc half-life is increased in mLANA-expressing cells. HEK 293T cells were
transfected with mLANA or control transfected. Cells were treated with cycloheximide (CHX, 100 mg/ml) for the times indicated (T0-T5). TCL were
analysed by immunoblotting as indicated. Bottom panel shows the densitometry analysis of Myc protein levels present in control (filled circles) or
mLANA transfected (open circles) cells, treated with CHX, normalised to Actin, assuming that Myc is 100% at time zero. (C) mLANA protects Myc from
Fbw7-mediated turnover. HEK 293T cells were transfected with the indicated plasmids. Cellular lysates were obtained and Myc protein levels were
assayed by immunoblotting. (D) Myc cellular levels in Fbw7 depleted cells are further increased by mLANA expression. HEK293T cells were
transfected with the indicated shRNA vectors. After culture, Myc protein levels were analysed by immunoblotting. (E) mLANA is able to compensate
the detrimental effect of b-TrCP depletion on Myc cellular levels. Cells were transfected with shRNA vectors and expressing plasmids, as depicted. Myc
levels were analysed by immunoblotting. 2, without; +, with; a-, anti; PD, pull-down; TCL, total cellular lysates.
doi:10.1371/journal.ppat.1003554.g005
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Collectively these results demonstrate that mLANA expression has
a positive effect on Myc cellular levels by preventing its
proteasomal turnover, thus prolonging its half-life, which is
associated with increased transcriptional activity.
EC5S
mLANA mimics SCFb-TrCP by antagonizing SCFFbw7-
mediated proteasomal turnover of Myc
Under physiological conditions Myc half-life is tightly regulated
through poly-ubiquitination by two distinct Skp1/Cul1/F-box
(SCF) E3 ubiquitin-ligases. That is, poly-ubiquitination of Myc by
SCFb-TrCP antagonizes SCFFbw7-mediated proteasomal dependent
turnover [6,8]. Therefore, we hypothesised if mLANA could be
modulating Myc stability by counteracting degradation by Fbw7
and mimicking the activity of b-TrCP. We overexpressed Fbw7
and analysed Myc cellular levels in the presence of co-expressed
mLANA. As expected, overexpression of Fbw7 led to a decrease in
Myc levels (Figure 5C, compare lanes 1 and 2). Overexpression of
Fbw7 had no effect on Myc levels when mLANA was concom-
itantly expressed (Figure 5C, compare lanes 3 and 4). Notably, the
antagonizing activity of mLANA towards Fbw7 was more
pronounced when compared with that afforded by b-TrCP
(Figure 5C, compare lanes 4 and 6). We further characterized
the mLANA effect on Fbw7 and b-TrCP interplay by depletion of
the expression of the two cellular E3 ubiquitin-ligases and analysis
of Myc levels. When Fbw7 was depleted Myc levels increased
further by the presence of mLANA (Figure 5D, compare lanes 3
and 4). In agreement, the turnover effect on Myc levels caused by
depletion of b-TrCP was counteracted by concomitant expression
of mLANA (Figure 5E, compare lanes 3 and 4). Together these
results demonstrate that mLANA mimics SCFb-TrCP by antago-
nizing SCFFbw7-mediated proteasomal turnover of Myc.
mLANA modulation of Myc activity is independent of the
phosphorylation status of Myc
Fbw7 control of Myc turnover is dependent on the interaction
between the ubiquitin-ligase and its substrate. Fbw7 recognizes
Myc when phosphorylated on threonine (T) 58 and catalyses its
poly-ubiquitination resulting in Myc proteasomal degradation
[6,7]. Phosphorylation of Myc on T58 is sequentially preceded by
phosphorylation on serine (S) 62, which activates and promotes
Myc stability [5]. Thus T58 and S62 are key phospho-residues
that regulate Myc activity at the protein level. Therefore, we set to
investigate the influence of Myc phosphorylation on the modula-
tory activity of mLANA. Using phospho-specific antibodies we
observed that under mLANA expression Myc is phosphorylated
on both S62 and T58 (Figure 6A, lane 2, first and second panels,
respectively). To analyse if sequential phosphorylation of Myc was
intact on mLANA expressing cells we proceed to substitute S62 or
T58 to alanines (A) on Myc and assess the phosphorylation status
of those Myc mutants. Compatible with the model of sequential
phosphorylation, in which phosphorylation of S62 precedes
phosphorylation of T58, MycT58A was readily phosphorylated
on S62, whereas MycS62A was not phosphorylated (Figure 6A,
lanes 3–6, first and second panels, respectively). Remarkably,
analysis of total Myc cellular levels revealed that, regardless of Myc
phosphorylation on either S62 or T58, co-expression of mLANA
led to increased Myc levels (Figure 6A, third panel). These data
not only demonstrate that mLANA is not interfering with Myc
phosphorylation, but also indicates that mLANA modulatory
functions override cellular pathways that control Myc activity.
Consistent with this hypothesis, mLANA is co-immunoprecipitat-
ed by both Myc mutants (Figure 6B), and it is able to mediate their
poly-ubiquitination (Figure 6C). Transcriptional activities of
MycT58A and MycS62A were also increased by expression of
mLANA (Figure 6D), further supporting that mLANA targets Myc
independently of cellular mechanisms of Myc regulation.
Discussion
In this study, we describe the first example of a viral protein
activating Myc transcriptional activity through increased protein
stability by mimicking a physiological post-translational regulatory
pathway. Modulation of Myc function was shown to be essential
for the lymphotropic c-herpesvirus MuHV-4 biology as infected
cells exhibit increased expression of known Myc target-genes, and
using a genetic approach, virus was found to amplify exclusively in
intact Myc GC B-cells. The molecular mechanism involved
heterotypic poly-ubiquitination of Myc mediated via the mLANA
protein encoded by ORF73. This was reminiscent of a newly
described pathway of Myc regulation through poly-ubiquitination.
Popov et al. showed that the cellular E3 ubiquitin-ligase SCFb-TrCP
uses UbcH5 ubiquitin-conjugating enzyme to form heterotypic
poly-ubiquitin chains on the N-terminus of Myc. Poly-ubiquitina-
tion of Myc by SCFb-TrCP leads to Myc stabilization and was
shown to antagonize SCFFbw7-mediated proteasomal turnover of
Myc [8]. Like SCFb-TrCP, EC5S
mLANA uses UbcH5 and antago-
nizes SCFFbw7. Furthermore, as previously demonstrated for
SCFb-TrCP, single substitutions of K33, K48 or K63 of ubiquitin
reduced or eliminated the ability of EC5S
mLANA to poly-
ubiquitinate, stabilize or increase the transcriptional activity of
Myc. However, our results suggest that the molecular mechanism
of mLANA modulation of Myc activity is not limited to Fbw7
antagonism. This is supported by the fact that mLANA protective
effects on Myc stability, in conditions of Fbw7 over expression, are
significantly more pronounced than observed for b-TrCP.
Moreover, mLANA was able to increase the stability and activity
of MycT58A, a Myc version that is not recognized by Fbw7. This
contrasts with what has been reported for b-TrCP that albeit being
able to poly-ubiquitinate MycT58A it did not impact on its
turnover [8]. Thus, the ability of mLANA to increase Myc
transcriptional activity through poly-ubiquitination, independently
of the phosphorylation status of Myc on S58 and T62, indicates
that this novel viral modulatory mechanism does not rely on post-
translation cellular regulation.
Modulation of host B-cell biology is of vital importance for c-
herpesviruses, as they depend critically on the expansion of latently
infected B-cell in GC reactions for host colonization. GC reactions
exhibit two distinct morphological areas. These include the dark
zone (DZ), where centroblasts are rapidly dividing, and the light
zone (LZ), where B-cells exit the cell cycle to differentiate into
plasma cells or memory B-cells or reenter the DZ for additional
rounds of cell division. Recently two studies have established the
importance of Myc for GC biology [13,14]. These studies show
that Myc expression is restricted to minute clusters of B-cells that
initiate GCs and a small fraction of LZ B-cells. Furthermore,
genetic interference with Myc expression or activity blocks GC
formation and results in the collapse of mature GCs. Combined
these studies demonstrate that expression of Myc is essential for
the initiation and maintenance of GCs preceding B-cell prolifer-
ation in the DZ. It has been proposed that the lack of Myc
expression in DZ B-cells, in conjunction with its short half-life,
settles strict limits on the number of cell divisions afforded by
centroblasts [27]. Therefore, by overriding the post-translational
physiological control of Myc and significantly prolonging its half-
life, mLANA favors an increase in the number of cell divisions
during the expansion of MuHV-4 infected B-cells in the GC
competitive niche. This modulation is likely to operate in infected
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B-cells at the initiation of a GC reaction and re-entry into the DZ.
This interpretation is consistent with the observation that around
70% of MuHV-4 infected GC B-cells are rapidly dividing
centroblasts versus approximately 20% infection in centrocytes.
However, we show here that MuHV-4 is not able to latently
expand in B-cells depleted of Myc expression. Hence, it is
dependent on previous expression of Myc in B-cells. This is
supported by our observation that MuHV-4 infected cells do not
exhibit increased levels of Myc mRNA. Combined, our data is in
good agreement with a post-translational mechanism of mLANA-
mediated Myc stabilization in latently infected B-cells to increase
their proliferative potential within GC reactions. This modulation
Figure 6. mLANA modulatory activity towards Myc is independent of Myc phosphorylation status. (A) HEK 293T cells were transfected
to express wild type Myc protein, or specific T58 or S62 residues mutated to alanines, with or without mLANA, as indicated and subjected to
immunoblotting analysis with phospho-specific antibodies directed towards Myc phosphorylated on S62 or T58. (B) In vivo interaction of Myc with
mLANA is independent of its phosphorylation on T58 and S62 residues. Cellular extracts from HEK 293T cells transfected with the indicated plasmids
were subjected to immunoprecipitation with anti-Myc and analysed by immunoblotting. (C & D) mLANA-mediated poly-ubiquitination and activation
of Myc is independent of Myc phosphorylation on T58 and S62 residues. (C) HEK 293T cells were transfected with the indicated combinations of
plasmids. Cellular lysates were obtained and subjected to Ni-NTA pull down as described in Figure 3F. (D) HeLa cells were transfected with a Myc (E-
box) luciferase reporter vector combined with plasmids for Myc, Myc phospho-mutants, with (grey bars) or without (open bars) mLANA, as indicated
and Myc transcriptional activity assayed as described in Figure 3C. Error bars represent SEM from triplicates from three independent transfection
experiments. 2, without; +, with; a-, anti; TCL, total cellular lysates.
doi:10.1371/journal.ppat.1003554.g006
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is compatible with the selective expression of mLANA within GC
B-cells [24] and its viral episomal maintenance properties [28].
By increasing the proliferative potential of latently infected GC
B-cells through the modulation of Myc, c-herpesviruses are
effectively promoting host colonization. However, different c-
herpesviruses have evolved distinct mechanisms to accomplish
Myc modulation. KSHV achieves this via LANA through a
mechanism that involves targeting of Gsk-3 [17] whereas EBV
appears to increase the transcription activity of Myc via interaction
of EBNA3C with SCFSkp2 [18]. However, how vital is Myc
modulation for c-herpesvirus host colonization? We have previ-
ously reported that EC5S
mLANA mediates poly-ubiquitination-
dependent proteosomal degradation of the NF-kB family member
p65/RelA [25]. In that study we demonstrate that a recombinant
MuHV-4 with a disrupted SOCS-box motif in mLANA loses the
ability of the virus to expand in GC B-cells and persist in the
mouse. Given that this recombinant lacks ubiquitin-ligase activity
we cannot ascribe its phenotype to NF-kB or Myc modulatory
effects since both activities depend on an intact SOCS-box motif.
We show here that mLANA interacts with Myc through a motif
independent of the SOCS-box and have shown before that this
also applies to interaction with p65/RelA [25]. We have mapped
both interactions to the N-terminal half of mLANA but have been
unable to identify any discrete binding motif to both cellular
targets (unpublished observations). Since structural modeling of
the N-terminal half of mLANA predicts it to be unstructured we
envisage that conformational rather than linear binding motifs
may be required for interaction of mLANA with p65/RelA and
Myc. Current mLANA structural studies in our laboratory are
addressing this question. However, the property of mLANA to
modulate both Myc and p56/RelA supports that maintenance of a
proliferative GC reaction through Myc stabilization requires
simultaneous inhibition of NF-kB signaling.
The molecular basis for EC5S
mLANA-mediated poly-ubiquitina-
tion of Myc and p65/RelA resulting in opposed outcomes is not
known. Effector proteins with ubiquitin binding domains (UBDs)
trigger specific cellular responses by recognizing different types of
ubiquitin topologies [26]. Hence, the decoration of Myc and p65/
RelA with distinct K-linkages and lengths by EC5S
mLANA may
determine distinct ubiquitin-mediated cellular functions. It is
interesting to note that in this respect a parallel exists between
EC5S
mLANA and SCFb-TrCP, as the latter also targets IkBa for
proteasomal-mediated degradation [29] whereas it promotes Myc
stabilization. The identification of UBD containing proteins that
discriminate poly-ubiquitin chains topologies, which determine
different biological outcomes is a field under intensive investiga-
tion. mLANA, therefore, provides as a good in vivo model for
future studies.
Herein, we described a novel viral mechanism of stabilization of
Myc through heterotypic poly-ubiquitination mediated by
mLANA. The findings presented sustain the interpretation that
increasing Myc stability is critical for the amplification of c-
herpesviruses in GC B-cells, thus persistence in the host.
Therefore, this study provides a pathogenesis link between Myc
and c-herpesviruses associated lymphoproliferative disease.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations of the Portuguese official Veterinary Directorate
(Portaria 1005/92). The Portuguese Experiments on Animal Act
strictly comply with the European Guideline 86/609/EEC and
follow the FELASA. Animal experiments were approved by the
Portuguese official veterinary department for welfare licensing
under the protocol number AEC_2010_017_PS_Rdt_General
and the IMM Animal Ethics Committee.
Reporter gene assays
For reporter gene assays, cells were transiently transfected with
500 ng of reporter vector, 1 mg of Myc and mLANA/mLANA–
SOCS expression plasmids. In all transfections, a Renilla luciferase
plasmid (10 ng) was used to normalise luciferase activity. Firefly
and Renilla luciferase activities were assayed using Dual-Luciferase
(Promega). Results are shown as fold induction relative to firefly
luciferase activity measured in control-transfected cells.
Cell cycle analysis
Cell cycle distribution profiles were analysed using Vybrant
DyeCycle Violet Stain (Invitrogen) according to the manufacter’s
instructions. Briefly, 24 h post-tranfection with GFP, GFP-
mLANA or GFP-mLANA-SOCS expressing plasmids, 16106
A20 cells were incubated with 1 ml of Vybrant DyeCycle in
complete RPMI for 30 minutes, at 37uC. The percentage of cells
in the various phases of cell cycle was determined using FlowJo
software (Tree Star, Inc), implementing the Dean-Jett-Fox model.
Three independent experiments were performed for each exper-
imental condition and a representative experiment is shown.
Immunoprecipitations
Cells were transiently transfected with plasmids encoding Myc
or Myc phospho- mutants (2 mg), ubiquitin or ubiquitin with
specific lysines mutated to arginines (4 mg), UbcH5 (2 mg) and/or
mLANA or mLANA-SOCS (2 mg). Cells were disrupted in
10 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100,
1 mM NaF, 100 mM Na3VO4 and protease inhibitors (Com-
plete; Roche). Supernatants were processed for immunoprecipita-
tion as described [30]. Analysis of Myc or K2 Myc ubiquitination
was performed under denaturing conditions (20 mM Tris–HCl
(pH 7.5), 5 mM EDTA, 1% SDS, 10 mM dithiothreitol and
Complete). Lysates were boiled for 10 minutes at 100uC, diluted
1/10 in lysis buffer and proceeded to immunoprecipitation.
Myc ubiquitination in vivo
Levels of in vivo ubiquitinated Myc were determined by pull-
down using Ni-NTA agarose beads. Cells were transfected with
plasmids carrying His6-ubiquitin (4 mg), Myc (2 mg), and/or
mLANA (2 mg). When indicated, cells were incubated for 8 hr
in 10 mM MG132 (Calbiochem). Transfected cells were lysed in
urea buffer (8M urea, 50 mM Tris-HCl (pH 7.5), 300 mM NaCl,
1% Triton X-100, 10 mM imidazole, 1 mM Na3VO4 and
Complete), incubated for 2 hr at 4uC with Ni-NTA beads that
were collected and washed with urea buffer. Proteins were eluted,
denatured by boiling in Laemmli’s buffer and analyzed by
immunoblotting.
Transcription analysis of Myc target genes
Total RNA from FACS-purified uninfected or infected GC B-
cells, or transfected HEK 293T cells or A20 B cells was extracted
with Trizol (Invitrogen). RNA (500 ng) was used for cDNA
synthesis (DyNAmo, Finnzymes). qPCR was performed using
DyNAmo Flash SYBR Green (Finnzymes). Primer sequences are
available in Table S1. All reactions were run in duplicates.
Amplification efficiencies and threshold cycle values were defined
by the fractional cycle number at which fluorescence crosses the
fixed threshold. Relative mRNA values, normalized to GAPDH,
were calculated by the Pfaffl method [31].
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Laboratory animals
Cc1-Cre mice were provided by Dr. Kurosaki (Japan), with the
agreement of Dr. Rajewsky and Dr. Casola. c-myc floxed mice were
a gift from Dr. Moreno de Albora´n (Spain). Cc1-creKI/WT; c-mycfl/fl
mice were generated by breeding heterozygous Cc1-cre mice [22],
with homozygous c-mycfl/fl mice [21]. Cc1-creWT/WT; c-mycfl/fl mice
littermates were used as controls. C57BL/6 mice were obtained
from Charles River Laboratories International Inc. Mice were
bred and housed at IMM. All experimental protocols were
performed in animals with 6–8 weeks of age.
Immunization and virus assays
Immunizations were performed via intraperitoneal injection with
100 mg NP-CGG (Biosearch Technologies, Inc.) adsorbed to 3 mg
of aluminium hydroxide (SERVA Electrophoresis GmbH), or
100 mg ovalbumin (OVA) grade V in CFA (Sigma). OVA
immunized mice were challenged 7 days post-primary immuniza-
tion with the same antigen/adjuvant combination. Inoculation of
MuHV-4 was performed intranasally with 104 p.f.u. in 20 ml of PBS
under halothane. Frequencies of MuHV-4 genome-positive cells in
GC B-cells were determined by limiting dilution combined with
real-time PCR as previously described [32]. GC B cells were FACS
purified from pools of five spleens using a BD FACSAria Flow
Cytometer (BD Biosciences) and serially two-fold diluted. Eight
replicates of each dilution were analysed by real time PCR (Rotor
Gene 6000, Corbett Life Science). The primer/probe sets were
specific for the MuHV-4 M9 gene (59 primer: GCCACGG-
TGGCCCTCTA; 39 primer: CAGGCCTCCCTCCCTTTG;
probe: 6-FAM-CTTCTGTTGATCTTCC–MGB). Samples were
subjected to a melting step of 95uC for 10 min followed by 40 cycles
of 15 s at 95uC and 1 min at 60uC. Real-time PCR data was
analyzed on the Rotor Gene 6000 software. The purity of sorted
cells was always greater than 97%, as analyzed by flow cytometry.
Plasmids, cell culture, DNA transfection and
immunological reagents
Information provided in protocols S1.
Supporting Information
Figure S1 UbcH5 is required for mLANA poly-ubiquiti-
nation of Myc. (A) mLANA immunoprecipitates exhibit E3
ubiquitin-ligase activity towards Myc, in vitro. Cell lysates from
transiently transfected HEK 293T cells expressing mLANA or
control transfected were subjected to immunoprecipitation with
polyclonal anti-mLANA rabbit serum. After three washes in lysis
buffer, immunoprecipitates were resuspended in reaction buffer
(40 mM HEPES [pH 7.4], 60 mM potassium acetate, 1 mM
EDTA, 2 mM DTT, 5 mM MgCl2, 10% glycerol). Myc was
generated by transfection of 293T cells with a HA-tagged Myc
expression plasmid, followed by immunoprecipitation with anti-
HA antibodies after 48 hours of culture. After washing in lysis
buffer, HA-Myc was eluted from beads using 0.5 mg/ml of HA
peptide (Sigma). Reactions were supplemented with recombinant
ubiquitin (2.5 mg) (Biomol International), E1 (50 ng), E2 (100 ng)
(Calbiochem), GST-RelA (2.5 mg) and ATP regenerating buffer
(Biomol International), when appropriate. Reactions were incu-
bated for 1 hour at 30uC. Proteins were eluted in reduced
Laemmli’s buffer, resolved by SDS-PAGE and analyzed by
immunoblotting with anti-ubiquitin antibody. (B) UbcH5 co-
immunoprecipitates with mLANA dependent on mLANA SOCS-
box motif. mLANA or mLANA-SOCS proteins were immuno-
precipitated from total cellular lysates from HEK 293T cells
transiently transfected with the expression plasmids (top). The
presence of UbcH5 in the immunoprecipitates was analysed by
immunoblotting. (C) mLANA-mediated activation of Myc is
dependent on endogenous UbcH5 expression. HeLa cells were
transfected with pSuper-puro vectors encoding control non-
targeting (grey bars) or UbcH5 (open bars) directed shRNAs,
along with the indicated expressing plasmids (bottom). Analysis of
Myc transcriptional activity associated with each experimental
condition was assessed as described in Figure 3C. Error bars
represent the standard error of the mean from three independent
experiments. 2, without; +, with; a-, anti; IP, immunoprecipita-
tion; TCL, total cellular lysates.
(TIFF)
Protocol S1 Plasmids, cell culture, DNA transfection
and immunological reagents. Description of plasmids and
immunological reagents utilized. Cell culture and DNA transfec-
tions procedures are described.
(DOCX)
Table S1 Oligonucleotides used for transcriptional
analysis of Myc target genes. Primers were designed using
qPrimerDepot database accessed at http://primerdepot.nci.nih.
gov or http://mouseprimerdepot.nci.nih.gov for human or mouse
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